1,49,000 units of secondary folding box board (FBB) were procured and plastic usage reduced by 1900 kg.
About 7525 kg of paper board (corrugated boxes) were procured and 128 trees were felled annually.
Stored approx. 300+ kg of chitosan obtained from 10.5 metric tons of shrimp waste
In line with its sustainability vision, Axio Biosolutions, a leading medical technology company, has very efficiently and effectively implemented Design for Environment (DfE) principles across its value chain in the organization. The brand ensures that its medical devices are made from environmentally sustainable materials and that its manufacturing processes are designed to minimize energy and water consumption. The business carefully selects recyclable packaging materials, which helps reduce the total environmental impact of its products.
Last year alone, Axio BioSolutions procured 1,49,000 units of secondary folding box board (FBB) and reduced plastic usage by 1900 kg. By going with recycled boxes, the brand saved around 7525 kg of paper board (corrugated boxes), thus saving 128 trees per year. Also, it stored approx. 300+ kg of chitosan derived from 10.5 metric tons of shrimp waste would have been dumped into the sea or land.
Sharing his views, Axio BioSolutions Assistant General Manager Mr. Saurabh Rawat said, “Designing for the environment is not just a responsibility; This is an opportunity to innovate and create a better future. By implementing DfE principles, we at Axio Bisolutions have reduced our carbon footprint and the environmental impact of our products. We have made significant efforts to ensure that our products are easily recyclable and disposed of in an environmentally responsible manner. This unwavering commitment helps us operate more sustainably and make the Earth healthier for generations to come.
In its quest for environmental sustainability, Axio BioSolutions has achieved many notable successes. The business ensures that the materials used to manufacture its medical devices are environmentally friendly, and it uses technologies that use less energy and water. A key concept at the DfE is the emphasis on developing systems, processes and products that are environmentally sustainable throughout their entire lifecycle. In the past, businesses have prioritized end product and financial benefits over long-term environmental impacts. Axio BioSolutions, on the other hand, has embraced DfE and integrated it into all areas of their business.
To solve the problem of waste management, chitosan, a biomaterial derived from the shells of crustaceans, is used, making it a renewable and biodegradable resource. Business recycles environmentally harmful waste using this new strategy. Axio BioSolutions contributes to the development of a more circular economy by reducing its environmental impact, cutting waste and relying on renewable resources.
The brand consciously collaborates with local suppliers, 80% of whom are local. The multiple environmental benefits of this system include reducing transportation emissions and supporting local economies, promoting transparency and accountability. From responsible sourcing of raw materials to environmentally friendly operations, Axio Biosolutions ensures that sustainability standards and ethical requirements are met by working with local vendors.
Responsible manufacturing practices, use of non-toxic, biodegradable chemicals and adherence to strict standards and regulations are all highly valued by Axio BioSolutions. The business ensures that the various wastes generated at its facilities are collected, transported and disposed of safely and responsibly, in compliance with all legal requirements.
By providing business transportation to 60% of the workforce, Axio BioSolutions supports employee sustainability by reducing the number of cars on the road and reducing greenhouse gas emissions. The company also encourages the use of alternative modes of transportation, such as public transportation and carpooling, to help reduce carbon footprints.
Axio Biosolutions has become a leader in the field of medical device manufacturing by adopting sustainable practices and implementing DfE principles. The organization’s dedication to environmental protection serves as a positive example for its peers, inspiring change in the sector.
About the company
Started in 2008, Axio Biosolutions is a Boston and Bengaluru-based innovative medical device company that has developed proprietary products (Axiostat & MaxioCel) using novel biomaterial-based technology for the hemostat and advanced wound care markets globally. The company has built a strong R&D portfolio with multiple global patents to its credit in the hemostat and wound healing space. Physicians worldwide use the company’s products in interventional cardiology for vascular bleeding control, trauma and emergency care. These products provide significant value compared to the current standard of care. The company’s flagship product line, Axiostat, is US FDA 510(k) cleared and EU CE-approved, and MaxioCel is EU CE-approved.